Jefferies analyst Thomas Wei reiterated a Buy rating and $80 price target on Incyte (NASDAQ: INCY) amid a physician panel ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE